Menu Search
Equities

Giant Biogene Holding Co Ltd

2367:HKG

Giant Biogene Holding Co Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (HKD)55.95
  • Today's Change-0.150 / -0.27%
  • Shares traded2.99m
  • 1 Year change+52.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Giant Biogene Holding Co Ltd grew revenues 49.05% from 2.36bn to 3.52bn while net income improved 44.88% from 1.00bn to 1.45bn.
Gross margin82.74%
Net profit margin39.53%
Operating margin47.65%
Return on assets30.24%
Return on equity37.30%
Return on investment36.89%
More ▼

Cash flow in CNYView more

In 2023, Giant Biogene Holding Co Ltd increased its cash reserves by 88.14%, or 1.17bn. The company earned 1.65bn from its operations for a Cash Flow Margin of 46.75%. In addition the company generated 51.81m cash from financing while 527.28m was spent on investing.
Cash flow per share1.99
Price/Cash flow per share29.36
Book value per share6.32
Tangible book value per share6.31
More ▼

Balance sheet in CNYView more

Giant Biogene Holding Co Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 2.50bn.
Current ratio3.81
Quick ratio3.62
Total debt/total equity0.0002
Total debt/total capital0.0002
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 3.66%.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)49.81%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-11.70
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.